Pre-Exposure Prophylaxis (PrEP) Initiation and Retention Among Young Kenyan Women.

Autor: Ohiomoba RO; Feinberg School of Medicine, Northwestern University, Chicago, USA. ramael.ohiomoba@northwestern.edu.; 175 East Delaware, Apt. 8708, Chicago, IL, 60611, USA. ramael.ohiomoba@northwestern.edu., Owuor PM; Department of Anthropology, Northwestern University, Evanston, USA.; Pamoja CBO, Kisumu, Kenya., Orero W; Pamoja CBO, Kisumu, Kenya., Were I; Pamoja CBO, Kisumu, Kenya., Sawo F; Pamoja CBO, Kisumu, Kenya., Ezema A; Feinberg School of Medicine, Northwestern University, Chicago, USA., Jackson-Gibson M; Feinberg School of Medicine, Northwestern University, Chicago, USA., Hirschhorn LR; Department of Medical Social Science, Feinberg School of Medicine, Northwestern University, Chicago, USA.; Institute of Global Health, Northwestern University, Chicago, USA.
Jazyk: angličtina
Zdroj: AIDS and behavior [AIDS Behav] 2022 Jul; Vol. 26 (7), pp. 2376-2386. Date of Electronic Publication: 2022 Jan 21.
DOI: 10.1007/s10461-022-03576-x
Abstrakt: The DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, Safe) Initiative works to reduce HIV infection among adolescent girls and young women (AGYW) through prevention interventions including Pre-Exposure Prophylaxis (PrEP). Pamoja CBO in Kisumu, Kenya implemented DREAMS. We describe PrEP initiation and persistence in 549 AGYW who started PrEP through Pamoja and factors associated with discontinuation. Median persistence time was 308 days (95% CI 245, 382) with 59% of AGYW discontinuing by the end of the study. The most common reasons for stopping PrEP were lack of perceived risk (27.9%) and relocation (18.7%). In the multivariable model, only age < 18 was associated with stopping PrEP. Younger age was associated with shorter time to discontinuation. Implementing PrEP through DREAMS was successful in supporting initiation of PrEP for AGYW. However, low rates of persistence at 1 year emphasizes the need for strategies to support PrEP persistence if HIV elimination is to be achieved.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: